Background. Acute renal dysfunction (ARD) may appear in heart transplant (HTx) patients both in the early
postoperative period and during follow-up, even after several years. CD25 is a subunit of the interleukin-2
receptor which is found exclusively on activated CD4 T lymphocytes. CD25 is crucial for clonal expansion of
anti-allograft host lymphocytes that mediate in acute rejection. There are experiences supporting the use of
Anti-CD25 monoclonal antibodies (MAb) immediately after HTx in patients with ARD as a bridge to renal function
recovery, allowing the temporary suspension of treatment with CNI.
Methods. In this study we report two cases of successful use of weekly MAb (basiliximab) in HTx patients who
developed late ARD after HTx.
Conclusions. In coclusion, we think that in cases of ARD where CNI therapy plays a key role, the use of weekly
doses of basiliximab allows CNI discontinuation until the restoration of renal function is achieved.
Basiliximab, CNI holiday, Heart transplant
Financial support: No grants or funding have been received for this
Pau Alonso La Fe University Hospital Bulevar sur s/n 46008 Valencia Valencia, Spain email@example.com
Share this Article
Related Content In Cardiovascular Disease
Foreword: Heart International. 2021;15(1):1
Welcome to the summer 2021 edition of Heart International. This issue contains 9 informative review articles on a range of topics which we hope will be of interest to all cardiovascular practitioners, regardless of subspecialism. We begin with a review by Chu and Gupta, who explore the use of etripamil nasal spray, a novel preparation […]
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]
Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk
Heart International. 2021;15(1):26-36 DOI: https://doi.org/10.17925/HI.2021.15.1.26
Coronary artery disease (CAD) is encountered on a daily basis in the field of medicine. Between 2009 and 2012, the global prevalence of CAD was 154 million, based on data from the Global Burden of Disease study; for the same period in the USA, it was approximately 15.5 million, based on data collected by the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!